Skip to content
Catalyst

PapersPMID:34758791

The use of Caralluma fimbriata as an appetite suppressant and weight loss supplement: a systematic review and meta-analysis of clinical trials.

BMC complementary medicine and therapies2021The record ↗

  1. Finding, moderate evidencelowersWaist circumference

What moved

1 findingHow to read these marks →
  • “Compared to placebo controlled group, C. fimbriata extract significantly reduced WC by − 1.59 cm (95% CI, − 3.07, − 0.10, p = 0.041; I2 = 32%, p = 0.23) and WHR by − 0.06 (95% CI, − 0.12, − 0.01, p = 0.05; I2 = 92%, p = 0.0003) respectively.”
    Study
    meta-analysis
    Effect
    −1.59 mean difference, 95% CI −3.07 to −0.1
    Dose studied
    CFE capsules, 0.5 g twice daily or 1 g/day across the pooled trials (Table 1)
    Population
    Adults with overweight or obesity in placebo-controlled randomised trials of Caralluma fimbriata extract, pooled

Study record

Design
meta-analysis
Species
human
Population
Clinical trials of Caralluma fimbriata extract in overweight or obese adults (BMI > 25 kg/m2), healthy adults, and children and adolescents with Prader-Willi syndrome
Participants
not reported
Comparator
placebo
Duration
not reported
Endpoints measured
16